Aging
Launched in 2009, Aging aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging.
The scope of the journal covers topics beyond traditional gerontology and aging research, including human age-related diseases such cancer, macular degeneration, Alzheimer’s disease among others. Lately, the journal was focusing on COVID-19 vulnerability as an age-dependent syndrome.
The journal’s collections distinctly reflect a journal’s dedication.
https://www.aging-us.com/special-collections-archive
Read moreless.
Cancer and aging are two sides of age-related tumorigenesis.
The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.
We welcome scientists from all disciplines, not only those in traditional gerontology. We aim to spread knowledge of the mechanisms surrounding aging and age-related disease, and ultimately seek to understand how to modulate these pathways to extend healthy life.
Launched in 2009, Aging is a peer-reviewed, traditional-style, biweekly journal with free access.
Accepted papers appear online and in PubMed very quickly.
Aging is indexed in PubMed/Medline (abbreviated as Aging (Albany NY), PubMed Central (abbreviated as Aging (Albany NY), Web of Science/Science Citation Index Expanded (abbreviated as Aging-US), Scopus (abbreviated as Aging), BIOSIS Previews, Biological Abstracts, and EMBASE. In 2018, Aging was invited to participate and in 2018-2022 (in 2022 META database was discontinued) was indexed in META, a world-renowned database of scientific literature.
All Aging content is archived in PubMed Central.The publisher also maintains the journal's own digital archive.
(IF) WEB OF SCIENCE
The Aging Editorial Board is composed of scientists from all over the world, predominantly from the USA. Among them are Cynthia Kenyon, Judith Campisi, Leonard Guarente, Michael Hall, Thomas Rando, and other outstanding scientists. The Board includes six members of the National Academy of Sciences (USA) and Lasker and Nobel Award recipients (Elizabeth H. Blackburn). It also includes the directors of some of the largest American cancer centers, directors of research from prominent pharmaceutical companies, professors from prestigious Universities, Editors of leading journals, and other prolific and distinguished scientists.
- PubMed/Medline (abbreviated as "Aging (Albany NY)"
- PubMed Central (abbreviated as "Aging (Albany NY)"
- Web of Science
- Scopus (abbreviated as Aging)
- Biological Abstracts
- BIOSIS Previews
- EMBASE
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
Aging has published outstanding papers and reviews by Lawrence Donehower, Toren Finkel, Stephen Helfand, Gerald Shadel, Andre Nussenzweig, Maurice Burg, Karen Vousden, Leonard Guarente, Dale Bredesen and other highly cited authors.
Elizabeth Blackburn, a member of the Editorial Board of Aging, won the Nobel Prize in Physiology or Medicine 2009 while a member of the Board. Elizabeth Blackburn co-authored a paper published in the inaugural issue of Aging.
Andrew V. Schally, a Nobel Prize Laureate, published a paper in Aging.
Shinya Yamanaka, who won the Nobel Prize in Physiology and Medicine 2012, has co-authored a paper published in Aging.
Aging is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Aging follows the COPE guidelines and ICMJE's Recommendations
Our mission is to share novel scientific discoveries across all fields of age-related research. We welcome scientists from all disciplines, not only those in traditional gerontology. We aim to spread knowledge of the mechanisms surrounding aging and age-related disease, and ultimately seek to understand how to affect these pathways to extend healthy life.
Join our Aging mailing list
Oncotarget
Oncotarget, launched in 2010, a primarily oncology-focused, peer-reviewed, open access journal. As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types and even tissues that can be viewed as targets relevant to cancer and other diseases as well. The term was introduced in the inaugural Editorial Introducing OncoTarget, by Mikhail Blagosklonny and Andrei Gudkov, https://doi.org/10.18632/oncotarget.101.
Read moreless.
Oncotarget aims to 1) maximize research impact through insightful peer-review, 2) eliminate borders between specialties by linking different fields of biomedical science, and 3) foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer, and other diseases as well. The term was introduced in the inaugural Editorial Introducing OncoTarget, by Mikhail Blagosklonny and Andrei Gudkov,
https://doi.org/10.18632/oncotarget.101.
Launched in 2010, Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form and released quickly to Pubmed.
Each paper can be printed on special demand.
Currently, more than 20,000 Oncotarget papers are searchable on PubMed.
Oncotarget is indexed in PubMed/Medline, PubMed Central, Scopus, and EMBASE. In 2018, Oncotarget was invited to participate and in 2018-2022 (in 2022 META was discontinued) was indexed in META, a world-renowned database of scientific literature. In all Indexes, the Journal's abbreviation is Oncotarget.
Oncotarget has published outstanding papers and reviews by Bert Vogelstein, Peter K. Vogt, Pier Paolo Pandolfi, Arnold J. Levine, Brian Druker, Carol Prives and other outstanding scientists.
Oncotarget is now offering free Altmetric Article Reports as a new part of our journal platform. This enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Oncotarget follows the COPE guidelines and ICMJE's Recommendations
Please check our Publication Ethics and Publication Malpractice statements
- PubMed/Medline
- PubMed Central
- Scopus
- EMBASE
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
Join our Oncotarget mailing list
Oncoscience
Launched in 2014, Oncoscience covers the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. Oncoscience also has a special mission: freeing researchers in oncology from publication costs. It is free for the readers and the authors.
Read moreless.
Oncoscience has also a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.
Launched in 2014, Oncoscience is a peer-reviewed, open access journal. Oncoscience also has a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.
As of January 1, 2021, Oncoscience has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form and released quickly to Pubmed.
All Oncoscience content is archived in PubMed Central.
The publisher also maintains the journal's own digital archive.
Oncoscience is indexed/abstracted in PubMed, PubMed Central, and EMBASE.
In 2018, Oncoscience was invited to participate and in 2018-2022 (in 2022 META database was discontinued) was indexed in META, a world-renowned database of scientific literature.
- PubMed
- PubMed Central
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
Oncoscience covers the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. Cancer research has entered a new phase in which the convergence of information from different disciplines (e.g., cancer biology, bioinformatics, chemistry, and drug design among others) is beginning to provide new insight into tumor development and cancer treatment.
To capture the key elements of this phase, Oncoscience covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, as well as their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, the journal covers the niche of interdisciplinary articles that bring together cancer biology, chemistry, and drug design.
Oncoscience also regularly publishes Editorials on emergent topics and commentaries on highly visible papers published in other journals.
Its international Editorial Board includes 65 members from different countries, including the USA (predominantly), United Kingdom, Sweden, France, Denmark and Spain. All are highly cited authors, professors at leading universities, and are supported by numerous NIH grants. The Editorial Board includes 20 members of the National Academy of Sciences (USA), 6 Lasker Award recipients (Brian Druker, Andrew Schally, Alexander Varshavsky, Stephen J. Elledge, William G. Kaelin,Jr., and Greg L. Semenza) and a Nobel Prize winner (Andrew Schally).
Our authors are from more than 25 countries on different continents.
Oncoscience is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Oncoscience always follows the COPE guidelines and ICMJE's Recommendations
Join our Oncoscience mailing list
Genes & Cancer
Formerly a SAGE publication, Genes & Cancer was acquired in 2014 and covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, including their roles in signal transduction and the mechanisms by which their expression and function are altered during tumor development. The Journal also invites papers in the areas of genomics, drug development and systems biology.
Read moreless.
Genes & Cancer (formerly a SAGE publication) was acquired in 2014. It is a peer-reviewed, open access journal.
As of January 1, 2021, Genes & Cancer has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form and released quickly to Pubmed.
All Genes & Cancer content is archived in PubMed Central.
The publisher also maintains the journal's own digital archive.
- PubMed
- PubMed Central
- Scopus (Cancer Research category)
- EMBASE
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
The journal covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, as well as their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. Genes & Cancer aims to capture the excitement of new phases of cancer research through genomics, bioinformatics and modern genetics.
Genes & Cancer is indexed/abstracted in PubMed, PubMed Central, Scopus (Cancer Research category), and EMBASE. In 2018, Genes & Cancer was invited to participate and in 2018-2022 (in 2022 META database was discontinued) was indexed in META, a world-renowned database of scientific literature.
Genes & Cancer is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Genes & Cancer always follows the COPE guidelines and ICMJE's Recommendations
Genes & Cancer is a member of the Committee on Publication Ethics (COPE)
Join our Genes mailing list
Launched in 2009, Aging aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging.
The scope of the journal covers topics beyond traditional gerontology and aging research, including human age-related diseases such cancer, macular degeneration, Alzheimer’s disease among others. Lately, the journal was focusing on COVID-19 vulnerability as an age-dependent syndrome.
The journal’s collections distinctly reflect a journal’s dedication.
https://www.aging-us.com/special-collections-archive
Read moreless.
Cancer and aging are two sides of age-related tumorigenesis.
The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.
We welcome scientists from all disciplines, not only those in traditional gerontology. We aim to spread knowledge of the mechanisms surrounding aging and age-related disease, and ultimately seek to understand how to modulate these pathways to extend healthy life.
Launched in 2009, Aging is a peer-reviewed, traditional-style, biweekly journal with free access.
Accepted papers appear online and in PubMed very quickly.
Aging is indexed in PubMed/Medline (abbreviated as Aging (Albany NY), PubMed Central (abbreviated as Aging (Albany NY), Web of Science/Science Citation Index Expanded (abbreviated as Aging-US), Scopus (abbreviated as Aging), BIOSIS Previews, Biological Abstracts, and EMBASE. In 2018, Aging was invited to participate and in 2018-2022 (in 2022 META database was discontinued) was indexed in META, a world-renowned database of scientific literature.
All Aging content is archived in PubMed Central.The publisher also maintains the journal's own digital archive.
(IF) WEB OF SCIENCE
The Aging Editorial Board is composed of scientists from all over the world, predominantly from the USA. Among them are Cynthia Kenyon, Judith Campisi, Leonard Guarente, Michael Hall, Thomas Rando, and other outstanding scientists. The Board includes six members of the National Academy of Sciences (USA) and Lasker and Nobel Award recipients (Elizabeth H. Blackburn). It also includes the directors of some of the largest American cancer centers, directors of research from prominent pharmaceutical companies, professors from prestigious Universities, Editors of leading journals, and other prolific and distinguished scientists.
- PubMed/Medline (abbreviated as "Aging (Albany NY)"
- PubMed Central (abbreviated as "Aging (Albany NY)"
- Web of Science
- Scopus (abbreviated as Aging)
- Biological Abstracts
- BIOSIS Previews
- EMBASE
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
Aging has published outstanding papers and reviews by Lawrence Donehower, Toren Finkel, Stephen Helfand, Gerald Shadel, Andre Nussenzweig, Maurice Burg, Karen Vousden, Leonard Guarente, Dale Bredesen and other highly cited authors.
Elizabeth Blackburn, a member of the Editorial Board of Aging, won the Nobel Prize in Physiology or Medicine 2009 while a member of the Board. Elizabeth Blackburn co-authored a paper published in the inaugural issue of Aging.
Andrew V. Schally, a Nobel Prize Laureate, published a paper in Aging.
Shinya Yamanaka, who won the Nobel Prize in Physiology and Medicine 2012, has co-authored a paper published in Aging.
Aging is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Aging follows the COPE guidelines and ICMJE's Recommendations
Our mission is to share novel scientific discoveries across all fields of age-related research. We welcome scientists from all disciplines, not only those in traditional gerontology. We aim to spread knowledge of the mechanisms surrounding aging and age-related disease, and ultimately seek to understand how to affect these pathways to extend healthy life.
Join our Aging mailing list
Oncotarget, launched in 2010, a primarily oncology-focused, peer-reviewed, open access journal. As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types and even tissues that can be viewed as targets relevant to cancer and other diseases as well. The term was introduced in the inaugural Editorial Introducing OncoTarget, by Mikhail Blagosklonny and Andrei Gudkov, https://doi.org/10.18632/oncotarget.101.
Read moreless.
Oncotarget aims to 1) maximize research impact through insightful peer-review, 2) eliminate borders between specialties by linking different fields of biomedical science, and 3) foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer, and other diseases as well. The term was introduced in the inaugural Editorial Introducing OncoTarget, by Mikhail Blagosklonny and Andrei Gudkov,
https://doi.org/10.18632/oncotarget.101.
Launched in 2010, Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form and released quickly to Pubmed.
Each paper can be printed on special demand.
Currently, more than 20,000 Oncotarget papers are searchable on PubMed.
Oncotarget is indexed in PubMed/Medline, PubMed Central, Scopus, and EMBASE. In 2018, Oncotarget was invited to participate and in 2018-2022 (in 2022 META was discontinued) was indexed in META, a world-renowned database of scientific literature. In all Indexes, the Journal's abbreviation is Oncotarget.
Oncotarget has published outstanding papers and reviews by Bert Vogelstein, Peter K. Vogt, Pier Paolo Pandolfi, Arnold J. Levine, Brian Druker, Carol Prives and other outstanding scientists.
Oncotarget is now offering free Altmetric Article Reports as a new part of our journal platform. This enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Oncotarget follows the COPE guidelines and ICMJE's Recommendations
Please check our Publication Ethics and Publication Malpractice statements
- PubMed/Medline
- PubMed Central
- Scopus
- EMBASE
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
Join our Oncotarget mailing list
Launched in 2014, Oncoscience covers the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. Oncoscience also has a special mission: freeing researchers in oncology from publication costs. It is free for the readers and the authors.
Read moreless.
Oncoscience has also a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.
Launched in 2014, Oncoscience is a peer-reviewed, open access journal. Oncoscience also has a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.
As of January 1, 2021, Oncoscience has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form and released quickly to Pubmed.
All Oncoscience content is archived in PubMed Central.
The publisher also maintains the journal's own digital archive.
Oncoscience is indexed/abstracted in PubMed, PubMed Central, and EMBASE.
In 2018, Oncoscience was invited to participate and in 2018-2022 (in 2022 META database was discontinued) was indexed in META, a world-renowned database of scientific literature.
- PubMed
- PubMed Central
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
Oncoscience covers the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. Cancer research has entered a new phase in which the convergence of information from different disciplines (e.g., cancer biology, bioinformatics, chemistry, and drug design among others) is beginning to provide new insight into tumor development and cancer treatment.
To capture the key elements of this phase, Oncoscience covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, as well as their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, the journal covers the niche of interdisciplinary articles that bring together cancer biology, chemistry, and drug design.
Oncoscience also regularly publishes Editorials on emergent topics and commentaries on highly visible papers published in other journals.
Its international Editorial Board includes 65 members from different countries, including the USA (predominantly), United Kingdom, Sweden, France, Denmark and Spain. All are highly cited authors, professors at leading universities, and are supported by numerous NIH grants. The Editorial Board includes 20 members of the National Academy of Sciences (USA), 6 Lasker Award recipients (Brian Druker, Andrew Schally, Alexander Varshavsky, Stephen J. Elledge, William G. Kaelin,Jr., and Greg L. Semenza) and a Nobel Prize winner (Andrew Schally).
Our authors are from more than 25 countries on different continents.
Oncoscience is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Oncoscience always follows the COPE guidelines and ICMJE's Recommendations
Join our Oncoscience mailing list
Formerly a SAGE publication, Genes & Cancer was acquired in 2014 and covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, including their roles in signal transduction and the mechanisms by which their expression and function are altered during tumor development. The Journal also invites papers in the areas of genomics, drug development and systems biology.
Read moreless.
Genes & Cancer (formerly a SAGE publication) was acquired in 2014. It is a peer-reviewed, open access journal.
As of January 1, 2021, Genes & Cancer has shifted to a continuous publishing model. Papers are now published continuously within yearly volumes in their final and complete form and released quickly to Pubmed.
All Genes & Cancer content is archived in PubMed Central.
The publisher also maintains the journal's own digital archive.
- PubMed
- PubMed Central
- Scopus (Cancer Research category)
- EMBASE
- META (Chan Zuckerberg Initiative) (2018-2022). META database was discontinued in 2022.
- Dimensions (Digital Science)
The journal covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, as well as their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. Genes & Cancer aims to capture the excitement of new phases of cancer research through genomics, bioinformatics and modern genetics.
Genes & Cancer is indexed/abstracted in PubMed, PubMed Central, Scopus (Cancer Research category), and EMBASE. In 2018, Genes & Cancer was invited to participate and in 2018-2022 (in 2022 META database was discontinued) was indexed in META, a world-renowned database of scientific literature.
Genes & Cancer is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.
Genes & Cancer always follows the COPE guidelines and ICMJE's Recommendations
Genes & Cancer is a member of the Committee on Publication Ethics (COPE)